Gomperts, S. N. et al. Imaging amyloid deposition in Lewy body diseases. Neurology 71, 903-910

Massachusetts General Hospital, Boston, MA 02114, USA.
Neurology (Impact Factor: 8.29). 10/2008; 71(12):903-10. DOI: 10.1212/01.wnl.0000326146.60732.d6
Source: PubMed


Extrapyramidal motor symptoms precede dementia in Parkinson disease (PDD) by many years, whereas dementia occurs early in dementia with Lewy bodies (DLB). Despite this clinical distinction, the neuropsychological and neuropathologic features of these conditions overlap. In addition to widespread distribution of Lewy bodies, both diseases have variable burdens of neuritic plaques and neurofibrillary tangles characteristic of Alzheimer disease (AD).
To determine whether amyloid deposition, as assessed by PET imaging with the beta-amyloid-binding compound Pittsburgh Compound B (PiB), can distinguish DLB from PDD, and to assess whether regional patterns of amyloid deposition correlate with specific motor or cognitive features.
Eight DLB, 7 PDD, 11 Parkinson disease (PD), 15 AD, and 37 normal control (NC) subjects underwent PiB-PET imaging and neuropsychological assessment. Amyloid burden was quantified using the PiB distribution volume ratio.
Cortical amyloid burden was higher in the DLB group than in the PDD group, comparable to the AD group. Amyloid deposition in the PDD group was low, comparable to the PD and NC groups. Relative to global cortical retention, occipital PiB retention was lower in the AD group than in the other groups. For the DLB, PDD, and PD groups, amyloid deposition in the parietal (lateral and precuneus)/posterior cingulate region was related to visuospatial impairment. Striatal PiB retention in the DLB and PDD groups was associated with less impaired motor function.
Global cortical amyloid burden is high in dementia with Lewy bodies (DLB) but low in Parkinson disease dementia. These data suggest that beta-amyloid may contribute selectively to the cognitive impairment of DLB and may contribute to the timing of dementia relative to the motor signs of parkinsonism.

Download full-text


Available from: Chester A Mathis
  • Source
    • "E ´ tudes Amyloide + Foster et al., 2010, Movement Disorders DCL 2/6 CTL 1/9, MP 1/8, MP-MCI 1/9, DPK 4/15 Edison et al., 2008, Journal of Neurology Neurosurgery and Psychiatry DCL 11/13 DPK 2/12, MP 0/10 Maetzler et al., 2009, Neurobiology of Disease DCL 4/9 MP 0/14, DPK 4/12 Gomperts et al., 2008, Neurology 2008 DCL 7/8 CTL 18/37, DPK 7/7, MA 15/15 "
    [Show abstract] [Hide abstract]
    ABSTRACT: Dementia with Lewy bodies (DLB) is the second cause of degenerative dementia in autopsy studies. In clinical pratice however, the prevalence of DLB is much lower with important intercenter variations. Among the reasons for this low sensitivity of DLB diagnosis are (1) the imprecision and subjectivity of the diagnostic criteria; (2) the underestimation of non-motor symptoms (REM-sleep behavior disorder, dysautonomia, anosmia); mostly (3) the nearly constant association of Lewy bodies with Alzheimer's disease pathology, which dominates the clinical phenotype. With the avenue of targeted therapies against the protein agregates, new clinical scales able to apprehend the coexistence of Lewy pathology in Alzheimer's disease are expected.
    Full-text · Article · Nov 2013 · Revue Neurologique
  • Source
    • "Although very attractive, the applicability of miRNAs as diagnostic tools into the clinic for AD (or MCI) will require extensive validation and follow-up studies in larger cohorts of patients. This is important as AD is a heterogeneous, multifactorial disease , with often display overlapping pathologies (e.g., Aβ deposits and Lewy bodies; Gomperts et al., 2008) and/or co-morbid diagnoses (e.g., diabetes, stroke). Obviously, the ultimate goal is to provide a sensitive, reproducible, and accurate detection of AD neuropathological changes prior to the onset of the disease and the appearance of the clinical symptoms. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Alzheimer's disease (AD) is the most common neurodegenerative disease in the elderly. While advancements have been made in understanding the genetic and molecular basis of AD, the clinical diagnosis of AD remains difficult, and post-mortem confirmation is often required. Furthermore, the onset of neurodegeneration precedes clinical symptoms by approximately a decade. Consequently, there is a crucial need for an early and accurate diagnosis of AD, which can potentially lead to strategies that can slow down or stop the progression of neurodegeneration and dementia. Recent advances in the non-coding RNA field have shown that microRNAs (miRNAs) can function as powerful biomarkers in human diseases. Studies are emerging suggesting that circulating miRNAs in the cerebrospinal fluid and blood serum have characteristic changes in AD patients. Whether miRNAs can be used in AD diagnosis, alone or in combination with other AD biomarkers (e.g., amyloid and tau), warrants further investigation.
    Full-text · Article · Aug 2013 · Frontiers in Molecular Neuroscience
  • Source
    • "However, decreases in Aβ 1–42 have also been demonstrated in other neurodegenerative disorders lacking distinct plaque pathology [54]. Additionally, in vivo plaque imaging has failed to demonstrate a correlation between plaque load and cognition in PD [55]. Therefore, these findings may suggest a different mechanism of Aβ protein processing, possibly related to synaptic α-synuclein pathology [56]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Mild Cognitive Impairment in Parkinson's Disease (PD-MCI) is common and may be associated with accelerated progression to dementia. Considering the importance of this emerging entity, new diagnostic criteria have recently been proposed. Early recognition and accurate classification of PD-MCI could offer opportunities for novel therapeutic interventions. This review discusses current definitions for PD-MCI, the screening tools used, the pattern of cognitive deficits observed, and the predictors of cognitive decline and transition to Parkinson's Disease Dementia. Emerging biomarkers, which may aid diagnosis, are also explored and the role of novel treatment options is considered.
    Full-text · Article · Jul 2013 · Neurology Research International
Show more